FourThought Financial Partners LLC Takes Position in Haleon PLC Sponsored ADR $HLN

FourThought Financial Partners LLC bought a new position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) during the second quarter, HoldingsChannel reports. The institutional investor bought 11,621 shares of the company’s stock, valued at approximately $121,000.

A number of other large investors have also added to or reduced their stakes in the company. Hanson & Doremus Investment Management increased its stake in Haleon by 234.1% during the 2nd quarter. Hanson & Doremus Investment Management now owns 2,372 shares of the company’s stock worth $25,000 after buying an additional 1,662 shares during the period. Golden State Wealth Management LLC boosted its position in Haleon by 107.6% in the 2nd quarter. Golden State Wealth Management LLC now owns 2,721 shares of the company’s stock valued at $28,000 after buying an additional 1,410 shares during the last quarter. Banque Transatlantique SA acquired a new stake in shares of Haleon during the first quarter valued at about $27,000. Ransom Advisory Ltd purchased a new stake in shares of Haleon during the first quarter worth about $31,000. Finally, Deutsche Bank AG increased its position in shares of Haleon by 267.8% during the first quarter. Deutsche Bank AG now owns 3,126 shares of the company’s stock worth $32,000 after acquiring an additional 2,276 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Trading Down 0.7%

Haleon stock opened at $9.76 on Thursday. Haleon PLC Sponsored ADR has a 1 year low of $8.71 and a 1 year high of $11.42. The firm’s 50-day moving average is $9.28 and its 200-day moving average is $9.86. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87. The company has a market cap of $43.44 billion, a P/E ratio of 25.01, a PEG ratio of 3.01 and a beta of 0.20.

Analyst Upgrades and Downgrades

HLN has been the subject of a number of analyst reports. The Goldman Sachs Group raised Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. Barclays cut Haleon from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, September 16th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.